Susanne Amler

Susanne Amler

Auto-generated profile, based on publicly available information

Susanne Amler

Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2016 in Blood
Verified
Journal Article
Closed access
PDF file
KMKlaus Metzeler H Metzeler
Klaus Metzeler H Metzeler
THTobias Herold
Tobias Herold
MRMaja Rothenberg-Thurley
Maja Rothenberg-Thurley
SASusanne Amler
Susanne Amler
MSMaria C. Sauerland
Maria C. Sauerland
KSKarsten Spiekermann
Karsten Spiekermann
The clinical and prognostic relevance of many recently identified driver gene mutations in adult acute myeloid leukemia (AML) is poorly defined. We sequenced the coding regions or hotspot areas of 68 recurrently mutated genes in a cohort of 664 patients aged 18 to 86 years treated on 2 phase 3 trials of the German AML Cooperative Group (AMLCG). The median number of 4 mutations per patient varied according to cytogenetic subgroup, age, and history of previous hematologic disorder or antineoplastic therapy. We found patterns of significantly comutated driver genes suggesting functional synergism. Conversely, we identified 8 virtually nonoverlapping patient subgroups, jointly comprising 78% of AML patients, that are defined by mutually exclusive genetic alterations. These subgroups, likely representing distinct underlying pathways of leukemogenesis, show widely divergent outcomes. Furthermore, we provide detailed information on associations between gene mutations, clinical patient characteristics, and therapeutic outcomes in this large cohort of uniformly treated AML patients. In multivariate analyses including a comprehensive set of molecular and clinical variables, we identified DNMT3A and RUNX1 mutations as important predictors of shorter overall survival (OS) in AML patients <60 years, and particularly in those with intermediate-risk cytogenetics. NPM1 mutations in the absence of FLT3-ITD, mutated TP53, and biallelic CEBPA mutations were identified as important molecular prognosticators of OS irrespective of patient age. In summary, our study provides a comprehensive overview of the spectrum, clinical associations, and prognostic relevance of recurrent driver gene mutations in a large cohort representing a broad spectrum and age range of intensively treated AML patients. Key Points We present comprehensive information on genetic driver events in a uniformly treated cohort of 664 adult AML patients aged 18 to 86 years. Mutations in NPM1, FLT3, CEBPA, TP53, and, in patients <60 years, DNMT3A and RUNX1, are the most important molecular risk factors in AML.

1 October 2009 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
GMGiovana Seno Di Marco
Giovana Seno Di Marco
SRStefan Reuter
Stefan Reuter
UHUta Hillebrand
Uta Hillebrand
SASusanne Amler
Susanne Amler
MKMaximilian König
Maximilian König
MBMarcus Brand
Marcus Brand
Endothelial dysfunction contributes to the increased cardiovascular risk that accompanies CKD. We hypothesized that the soluble VEGF receptor 1 (sFlt-1), a VEGF antagonist, plays a role in endothelial dysfunction and decreased angiogenesis in CKD. We enrolled 130 patients with CKD stages 3 to 5 and 56 age- and gender-matched control patients. Plasma sFlt-1 levels were higher in patients with CKD and, after multivariate regression analyses, exclusively associated with renal function and levels of vWF, a marker of endothelial dysfunction. Compared with serum from control patients, both recombinant sFlt-1 and serum from patients with CKD had antiangiogenic activity in the chick chorioallantoic membrane (CAM) assay, induced endothelial cell apoptosis in vitro, and decreased nitric oxide generation in two different endothelial cell lines. Pretreating the sera with an antibody against sFlt-1 abrogated all of these effects. Furthermore, we observed increased sFlt1 levels in 5/6-nephrectomized rats compared with sham-operated animals. Finally, using real-time PCR and ELISA, we identified monocytes as a possible source of increased sFlt-1 in patients with CKD. Our findings show that excess sFlt-1 associates with endothelial dysfunction in CKD and suggest that increased sFlt-1 may predict cardiovascular risk in CKD.

1 January 2013 in Autoimmunity Reviews
Verified
Journal Article
Closed access
CBCyrus Biazar
Cyrus Biazar
JSJohanna Sigges
Johanna Sigges
NPNikolaos Patsinakidis
Nikolaos Patsinakidis
VRVincent Ruland
Vincent Ruland
SASusanne Amler
Susanne Amler
AKAnnegret Kuhn
Annegret Kuhn

1 January 2013 in Heart Rhythm
Verified
Journal Article
Closed access
JKJulia Köbe
Julia Köbe
FRFlorian Reinke
Florian Reinke
CMChristian Meyer
Christian Meyer
DSDong-In Shin
Dong-In Shin
EMEimo Martens
Eimo Martens
LELars Eckardt
Lars Eckardt

12 April 2010 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
AKA. Kuhn
A. Kuhn
SAS. Amler
S. Amler
SBS. Beissert
S. Beissert
MBM. Böhm
M. Böhm
RBR. Brehler
R. Brehler
GBG. Bonsmann
G. Bonsmann

1 February 2013 in Kidney International
Verified
Journal Article
Open access
PDF file
GMGiovana Seno Di Marco
Giovana Seno Di Marco
MKMaximilian König
Maximilian König
CSChristian Stock
Christian Stock
AWAnne Wiesinger
Anne Wiesinger
UHUta Hillebrand
Uta Hillebrand
MBMarcus Brand
Marcus Brand
Hyperphosphatemia is associated with increased cardiovascular risk in patients with renal disease and in healthy individuals. Here we tested whether high phosphate has a role in the pathophysiology of cardiovascular events by interfering with endothelial function, thereby impairing microvascular function and angiogenesis. Protein expression analysis found downregulation of annexin II in human coronary artery endothelial cells, an effect associated with exacerbated shedding of annexin II–positive microparticles by the cells exposed to high phosphate media. EAhy926 endothelial cells exposed to sera from hyperphosphatemic patients also display decreased annexin II, suggesting a negative correlation between serum phosphate and annexin II expression. By using endothelial cell–based assays in vitro and the chicken chorioallantoic membrane assay in vivo, we found that angiogenesis, vessel wall morphology, endothelial cell migration, capillary tube formation, and endothelial survival were impaired in a hyperphosphatemic milieu. Blockade of membrane-bound extracellular annexin II with a specific antibody mimicked the effects of high phosphate. In addition, high phosphate stiffened endothelial cells in vitro and in rats in vivo. Thus, our results link phosphate and adverse clinical outcomes involving the endothelium in both healthy individuals and patients with renal disease.